Follow-Up to the August 2008 Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as Vytorin), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as Zetia) - FDA Investigates a Report from the SEAS Trial
Links shared publicly online about this topic.
- 1,512total visits
Follow-Up to the August 2008 Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as Vytorin), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as Zetia) - FDA Investigates a Report from the SEAS Trial
fda.gov —
In august 2008, the u.s. food and drug administration (fda) issued an early communication describing a possible association between the use of vytorin – a combination of simvastatin (zocor) and ezetimibe (zetia) – and an increased risk of cancer and cancer-related death compared to placebo.
View full resource at fda.gov
Tags: Cholesterol Medication, Cancer, Drug, FDA, Zocor, Vytorin, Zetia
Most Recently Shared on December 22, 2009 at 4:43 pm By:
RT @FDA_Drug_Info: Follow-Up to the Aug. 2008 Early Communication on Vytorin, Zetia, Zocor and the SEAS Trial. http://bit.ly/FU_SEAS
Advertisement
